Defibrotide lowers rates of veno-occlusive disease after transplant

02/24/2012 | DoctorsLounge.com

Defibrotide prophylaxis can reduce cases of hepatic veno-occlusive disease among patients younger than 18 undergoing hematopoietic stem cell transplantation, German researchers found. The study in The Lancet journal showed that 12% of patients who received the drug developed veno-occlusive disease 30 days after transplantation, compared with 20% in the control group.

View Full Article in:

DoctorsLounge.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY